NYSE:DOCSHealthcare Services
Is Analyst Upgrades on AI Workflow and Pharma Ads Altering The Investment Case For Doximity (DOCS)?
In recent days, Doximity has attracted multiple analyst upgrades, with firms such as Morgan Stanley and Raymond James citing its strong free cash flow, expanding AI-enabled workflow tools, and growing clinician engagement as reasons for a more positive business outlook.
Analysts also highlighted Doximity’s potential to benefit if tighter rules on direct-to-consumer drug advertising push pharmaceutical companies to shift more of their marketing budgets onto its platform.
Next, we’ll examine...